Enzo Announces Issuance of U.S. Patent for Methods of Using Proprietary Compound SK1-I in Patients; Exploring Options for Development as a Potential Treatment for COVID-19

Stock Information for Enzo Biochem Inc. ($0.01 Par Value)

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Enzo Biochem Inc. ($0.01 Par Value)

Enzo Biochem Reports Second Quarter Fiscal 2024 Results and Provides Business Update
Enzo Biochem Reports Results of its Annual Meeting of Shareholders and Officer Appointments
ENZO BIOCHEM REPORTS FIRST QUARTER FISCAL 2024 RESULTS AND PROVIDES BUSINESS UPDATE
ENZO BIOCHEM REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 RESULTS AND PROVIDES BUSINESS UPDATE
Steven J. Pully Appointed to Enzo Biochem's Board of Directors
Enzo Biochem Announces Departure of Hamid Erfanian and Appointment of Kara Cannon as Interim CEO
Enzo Biochem Completes Sale of Clinical Laboratory to Labcorp
Enzo Biochem Reports Third Quarter Fiscal Year 2023 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.